[
  {
    "question": {
      "question_id": "cs03_q03_longitudinal",
      "scope_id": "clinical_signal_03",
      "checkpoint_after": 25,
      "question_type": "longitudinal",
      "prompt": "What is driving the hepatic adverse events in this trial?",
      "ground_truth": {
        "canonical_answer": "A drug-drug interaction between LNS-4821 and concomitant statin therapy (atorvastatin) via CYP3A4 inhibition. The hepatotoxicity signal is in the statin subgroup across all sites, not a site-specific lab issue. The Site 07 equipment hypothesis was a red herring.",
        "required_evidence_refs": [
          "clinical_signal_03_ep_010",
          "clinical_signal_03_ep_018",
          "clinical_signal_03_ep_023",
          "clinical_signal_03_ep_015"
        ],
        "key_facts": [
          "ALT elevations are concentrated in subjects receiving concurrent statin therapy, with higher-dose statin subgroups showing proportionally greater enzyme increases",
          "multi-site signal distribution rules out site-specific confounders as causal explanation",
          "the hepatic enzyme pattern is consistent with a drug-drug interaction mediated through shared hepatic metabolism pathways, not direct hepatotoxicity",
          "Site 07 lab equipment issue is not the cause of ALT elevations",
          "the adverse signal is hepatic (ALT/AST elevation), not renal \u2014 kidney function markers remain stable while liver enzymes diverge"
        ]
      }
    },
    "answer": {
      "question_id": "cs03_q03_longitudinal",
      "answer_text": "The provided documents do not contain specific information about the cause of hepatic adverse events in the trial. While several documents mention enrollment data and concomitant statin use across sites [clinical_signal_03_ep_020][clinical_signal_03_ep_022][clinical_signal_03_ep_017], none explicitly link these or other factors to hepatic adverse events or identify a root cause. Further details would be needed to determine the driving factors.",
      "turns": [
        {
          "role": "assistant",
          "content": "",
          "tool_calls": [
            {
              "id": "call_14fb1611c96d42378db200b9",
              "name": "memory_capabilities",
              "arguments": {}
            }
          ],
          "tokens_used": 745
        },
        {
          "role": "tool",
          "tool_results": [
            {
              "tool_call_id": "call_14fb1611c96d42378db200b9",
              "content": "{\"search_modes\": [\"keyword\", \"semantic\"], \"filter_fields\": [{\"name\": \"scope_id\", \"field_type\": \"string\", \"description\": \"Filter by scope ID\", \"enum_values\": null}, {\"name\": \"start_date\", \"field_type\": \"string\", \"description\": \"Filter episodes after this ISO date\", \"enum_values\": null}, {\"name\": \"end_date\", \"field_type\": \"string\", \"description\": \"Filter episodes before this ISO date\", \"enum_values\": null}], \"max_results_per_search\": 7, \"supports_date_range\": true, \"extra_tools\": [{\"name\": \"batch_retrieve\", \"description\": \"Retrieve multiple full documents by their reference IDs in a single call. PREFER this over calling memory_retrieve multiple times \\u2014 it is far more efficient and uses only one tool call instead of one per document. After memory_search, pass all ref_ids you want to read to this tool.\", \"parameters\": {\"type\": \"object\", \"properties\": {\"ref_ids\": {\"type\": \"array\", \"items\": {\"type\": \"string\"}, \"description\": \"List of reference IDs to retrieve (from search results).\"}}, \"required\": [\"ref_ids\"]}}]}",
              "is_error": false
            }
          ],
          "tokens_used": 0
        },
        {
          "role": "assistant",
          "content": "",
          "tool_calls": [
            {
              "id": "call_59d5d0c9816a47a89e5b54e3",
              "name": "memory_search",
              "arguments": {
                "query": "hepatic adverse events trial cause",
                "limit": 7
              }
            }
          ],
          "tokens_used": 1045
        },
        {
          "role": "tool",
          "tool_results": [
            {
              "tool_call_id": "call_59d5d0c9816a47a89e5b54e3",
              "content": "[{\"ref_id\": \"clinical_signal_03_ep_020\", \"text\": \"## 2024-07-15 Daily Operations Summary\\n\\n### Enrollment\\n- Total Randomized: 216\\n- Active: 206\\n- Screen Failures Cumulative: 45\\n- Withdrawals Cumulative: 10\\n\\n#### Sites\\n- Site 01 Enrolled: 22\\n- Site 01 Active: 22\\n- Site 01 Statin Concomitant: 7\\n- Site 02 Enrolled: 16\\n- Site 02 Active: 16\\n- Site 02 Statin Concomitant: 5\\n- Site 03 Enrolled: 20\\n- Site 03 Active: 20\\n- Site 03 Statin Concomitant: 6\\n- Site 04 Enrolled: 14\\n- Site 04 Active: 14\\n- Site 04 Statin Concomitant: 4\\n- Site 05 Enrolled: 18\\n- Site\", \"score\": 0.032018442622950824, \"metadata\": {\"episode_type\": \"signal\", \"phase\": \"escalation\", \"signal_density\": \"high\"}}, {\"ref_id\": \"clinical_signal_03_ep_022\", \"text\": \"## 2024-07-29 Daily Operations Summary\\n\\n### Enrollment\\n- Total Randomized: 236\\n- Active: 230\\n- Screen Failures Cumulative: 50\\n- Withdrawals Cumulative: 6\\n\\n#### Sites\\n- Site 01\\n  - Enrolled: 24\\n  - Active: 24\\n  - Statin Concomitant: 7\\n- Site 02\\n  - Enrolled: 18\\n  - Active: 18\\n  - Statin Concomitant: 5\\n- Site 03\\n  - Enrolled: 22\\n  - Active: 22\\n  - Statin Concomitant: 7\\n- Site 04\\n  - Enrolled: 16\\n  - Active: 16\\n  - Statin Concomitant: 4\\n- Site 05\\n  - Enrolled: 20\\n  - Active: 20\\n  - Statin Concomita\", \"score\": 0.031544957774465976, \"metadata\": {\"episode_type\": \"signal\", \"phase\": \"escalation\", \"signal_density\": \"high\"}}, {\"ref_id\": \"clinical_signal_03_ep_017\", \"text\": \"## 2024-06-24 Daily Operations Summary\\n\\n### Enrollment\\n- Total Randomized: 225\\n- Active: 214\\n- Screen Failures Cumulative: 30\\n- Withdrawals Cumulative: 11\\n\\n#### Sites\\n- Site 01 Enrolled: 23\\n- Site 01 Active: 23\\n- Site 01 Statin Concomitant: 7\\n- Site 02 Enrolled: 17\\n- Site 02 Active: 17\\n- Site 02 Statin Concomitant: 5\\n- Site 03 Enrolled: 21\\n- Site 03 Active: 21\\n- Site 03 Statin Concomitant: 6\\n- Site 04 Enrolled: 15\\n- Site 04 Active: 15\\n- Site 04 Statin Concomitant: 3\\n- Site 05 Enrolled: 19\\n- Site\", \"score\": 0.03125763125763126, \"metadata\": {\"episode_type\": \"signal\", \"phase\": \"escalation\", \"signal_density\": \"high\"}}, {\"ref_id\": \"clinical_signal_03_ep_024\", \"text\": \"## 2024-08-12 Daily Operations Summary\\n\\n### Enrollment\\n- Total Randomized: 244\\n- Active: 236\\n- Screen Failures Cumulative: 49\\n- Withdrawals Cumulative: 8\\n\\n### Sites\\n- Site 01\\n  - Enrolled: 25\\n  - Active: 25\\n  - Statin Concomitant: 6\\n- Site 02\\n  - Enrolled: 18\\n  - Active: 18\\n  - Statin Concomitant: 5\\n- Site 03\\n  - Enrolled: 22\\n  - Active: 22\\n  - Statin Concomitant: 7\\n- Site 04\\n  - Enrolled: 16\\n  - Active: 16\\n  - Statin Concomitant: 5\\n- Site 05\\n  - Enrolled: 20\\n  - Active: 20\\n  - Statin Concomitan\", \"score\": 0.030834914611005692, \"metadata\": {\"episode_type\": \"signal\", \"phase\": \"root_cause\", \"signal_density\": \"high\"}}, {\"ref_id\": \"clinical_signal_03_ep_011\", \"text\": \"## 2024-05-13 Daily Operations Summary\\n\\n### Enrollment\\n- Total Randomized: 189\\n- Active: 182\\n- Screen Failures Cumulative: 27\\n- Withdrawals Cumulative: 7\\n\\n#### Sites\\n- Site 01\\n  - Enrolled: 19\\n  - Active: 19\\n  - Statin Concomitant: 5\\n- Site 02\\n  - Enrolled: 14\\n  - Active: 14\\n  - Statin Concomitant: 3\\n- Site 03\\n  - Enrolled: 17\\n  - Active: 17\\n  - Statin Concomitant: 5\\n- Site 04\\n  - Enrolled: 12\\n  - Active: 12\\n  - Statin Concomitant: 3\\n- Site 05\\n  - Enrolled: 16\\n  - Active: 16\\n  - Statin Concomita\", \"score\": 0.02967032967032967, \"metadata\": {\"episode_type\": \"signal\", \"phase\": \"early_signal\", \"signal_density\": \"low\"}}, {\"ref_id\": \"clinical_signal_03_ep_013\", \"text\": \"## 2024-05-27 Daily Operations Summary\\n\\n### Enrollment\\n- Total Randomized: 195\\n- Active: 191\\n- Screen Failures Cumulative: 29\\n- Withdrawals Cumulative: 4\\n\\n#### Sites\\n- Site 01\\n  - Enrolled: 19\\n  - Active: 19\\n  - Statin Concomitant: 5\\n- Site 02\\n  - Enrolled: 14\\n  - Active: 14\\n  - Statin Concomitant: 4\\n- Site 03\\n  - Enrolled: 18\\n  - Active: 18\\n  - Statin Concomitant: 5\\n- Site 04\\n  - Enrolled: 13\\n  - Active: 13\\n  - Statin Concomitant: 4\\n- Site 05\\n  - Enrolled: 16\\n  - Active: 16\\n  - Statin Concomita\", \"score\": 0.029418126757516764, \"metadata\": {\"episode_type\": \"signal\", \"phase\": \"early_signal\", \"signal_density\": \"low\"}}, {\"ref_id\": \"clinical_signal_03_ep_018\", \"text\": \"## 2024-07-01 Daily Operations Summary\\n\\n### Enrollment\\n- Total Randomized: 210\\n- Active: 204\\n- Screen Failures Cumulative: 53\\n- Withdrawals Cumulative: 6\\n\\n#### Sites\\n- Site 01 Enrolled: 21\\n- Site 01 Active: 21\\n- Site 01 Statin Concomitant: 7\\n- Site 02 Enrolled: 16\\n- Site 02 Active: 16\\n- Site 02 Statin Concomitant: 4\\n- Site 03 Enrolled: 19\\n- Site 03 Active: 19\\n- Site 03 Statin Concomitant: 5\\n- Site 04 Enrolled: 14\\n- Site 04 Active: 14\\n- Site 04 Statin Concomitant: 4\\n- Site 05 Enrolled: 17\\n- Site \", \"score\": 0.028958333333333336, \"metadata\": {\"episode_type\": \"signal\", \"phase\": \"escalation\", \"signal_density\": \"high\"}}]",
              "is_error": false
            }
          ],
          "tokens_used": 0
        },
        {
          "role": "assistant",
          "content": "",
          "tool_calls": [
            {
              "id": "call_671189f30c1e4f2d9abdf0d7",
              "name": "batch_retrieve",
              "arguments": {
                "ref_ids": [
                  "clinical_signal_03_ep_020",
                  "clinical_signal_03_ep_022",
                  "clinical_signal_03_ep_017",
                  "clinical_signal_03_ep_024",
                  "clinical_signal_03_ep_011",
                  "clinical_signal_03_ep_013",
                  "clinical_signal_03_ep_018"
                ]
              }
            }
          ],
          "tokens_used": 3244
        },
        {
          "role": "tool",
          "tool_results": [
            {
              "tool_call_id": "call_671189f30c1e4f2d9abdf0d7",
              "content": "[Context budget exhausted \u2014 synthesize answer from evidence already retrieved]",
              "is_error": false
            }
          ],
          "tokens_used": 0
        },
        {
          "role": "assistant",
          "content": "The provided documents do not contain specific information about the cause of hepatic adverse events in the trial. While several documents mention enrollment data and concomitant statin use across sites [clinical_signal_03_ep_020][clinical_signal_03_ep_022][clinical_signal_03_ep_017], none explicitly link these or other factors to hepatic adverse events or identify a root cause. Further details would be needed to determine the driving factors.",
          "tokens_used": 3368
        }
      ],
      "tool_calls_made": 3,
      "total_tokens": 8402,
      "wall_time_ms": 10089.85948190093,
      "budget_violations": [
        "Cumulative result token limit exceeded: 8338 > 2048"
      ],
      "refs_cited": [
        "clinical_signal_03_ep_020",
        "clinical_signal_03_ep_022",
        "clinical_signal_03_ep_017"
      ]
    },
    "retrieved_ref_ids": [
      "clinical_signal_03_ep_020",
      "clinical_signal_03_ep_022",
      "clinical_signal_03_ep_017"
    ],
    "valid_ref_ids": [
      "clinical_signal_03_ep_020",
      "clinical_signal_03_ep_022",
      "clinical_signal_03_ep_017"
    ]
  },
  {
    "question": {
      "question_id": "cs03_q06_paraphrase",
      "scope_id": "clinical_signal_03",
      "checkpoint_after": 25,
      "question_type": "paraphrase",
      "prompt": "Why are liver enzymes elevated in a subset of trial participants?",
      "ground_truth": {
        "canonical_answer": "A drug-drug interaction between LNS-4821 and concomitant statin therapy (atorvastatin) via CYP3A4 inhibition. The hepatotoxicity signal is in the statin subgroup across all sites, not a site-specific lab issue. The Site 07 equipment hypothesis was a red herring.",
        "required_evidence_refs": [
          "clinical_signal_03_ep_010",
          "clinical_signal_03_ep_018",
          "clinical_signal_03_ep_023",
          "clinical_signal_03_ep_015"
        ],
        "key_facts": [
          "ALT elevations are concentrated in subjects receiving concurrent statin therapy, with higher-dose statin subgroups showing proportionally greater enzyme increases",
          "multi-site signal distribution rules out site-specific confounders as causal explanation",
          "the hepatic enzyme pattern is consistent with a drug-drug interaction mediated through shared hepatic metabolism pathways, not direct hepatotoxicity",
          "Site 07 lab equipment issue is not the cause of ALT elevations"
        ]
      }
    },
    "answer": {
      "question_id": "cs03_q06_paraphrase",
      "answer_text": "The provided documents do not contain specific information explaining why liver enzymes are elevated in a subset of trial participants. While several documents mention enrollment data and concomitant statin use across sites [ref_id: clinical_signal_03_ep_021, ref_id: clinical_signal_03_ep_023, ref_id: clinical_signal_03_ep_018], none directly address the underlying cause of elevated liver enzymes. Further investigation or additional data may be required to determine the cause.",
      "turns": [
        {
          "role": "assistant",
          "content": "",
          "tool_calls": [
            {
              "id": "call_233e970ee17944e280b7ba66",
              "name": "memory_capabilities",
              "arguments": {}
            }
          ],
          "tokens_used": 745
        },
        {
          "role": "tool",
          "tool_results": [
            {
              "tool_call_id": "call_233e970ee17944e280b7ba66",
              "content": "{\"search_modes\": [\"keyword\", \"semantic\"], \"filter_fields\": [{\"name\": \"scope_id\", \"field_type\": \"string\", \"description\": \"Filter by scope ID\", \"enum_values\": null}, {\"name\": \"start_date\", \"field_type\": \"string\", \"description\": \"Filter episodes after this ISO date\", \"enum_values\": null}, {\"name\": \"end_date\", \"field_type\": \"string\", \"description\": \"Filter episodes before this ISO date\", \"enum_values\": null}], \"max_results_per_search\": 7, \"supports_date_range\": true, \"extra_tools\": [{\"name\": \"batch_retrieve\", \"description\": \"Retrieve multiple full documents by their reference IDs in a single call. PREFER this over calling memory_retrieve multiple times \\u2014 it is far more efficient and uses only one tool call instead of one per document. After memory_search, pass all ref_ids you want to read to this tool.\", \"parameters\": {\"type\": \"object\", \"properties\": {\"ref_ids\": {\"type\": \"array\", \"items\": {\"type\": \"string\"}, \"description\": \"List of reference IDs to retrieve (from search results).\"}}, \"required\": [\"ref_ids\"]}}]}",
              "is_error": false
            }
          ],
          "tokens_used": 0
        },
        {
          "role": "assistant",
          "content": "",
          "tool_calls": [
            {
              "id": "call_57c1c6ade53f4d87ad80a511",
              "name": "memory_search",
              "arguments": {
                "query": "elevated liver enzymes in trial participants",
                "limit": 7
              }
            }
          ],
          "tokens_used": 1046
        },
        {
          "role": "tool",
          "tool_results": [
            {
              "tool_call_id": "call_57c1c6ade53f4d87ad80a511",
              "content": "[{\"ref_id\": \"clinical_signal_03_ep_021\", \"text\": \"## 2024-07-22 Daily Operations Summary\\n\\n### Enrollment\\n- Total Randomized: 219\\n- Active: 209\\n- Screen Failures Cumulative: 35\\n- Withdrawals Cumulative: 10\\n\\n#### Sites\\n- Site 01 Enrolled: 22\\n- Site 01 Active: 22\\n- Site 01 Statin Concomitant: 5\\n- Site 02 Enrolled: 16\\n- Site 02 Active: 16\\n- Site 02 Statin Concomitant: 4\\n- Site 03 Enrolled: 20\\n- Site 03 Active: 20\\n- Site 03 Statin Concomitant: 5\\n- Site 04 Enrolled: 14\\n- Site 04 Active: 14\\n- Site 04 Statin Concomitant: 4\\n- Site 05 Enrolled: 18\\n- Site\", \"score\": 0.03200204813108039, \"metadata\": {\"episode_type\": \"signal\", \"phase\": \"escalation\", \"signal_density\": \"high\"}}, {\"ref_id\": \"clinical_signal_03_ep_023\", \"text\": \"## 2024-08-05 Daily Operations Summary\\n\\n### Enrollment\\n- Total Randomized: 210\\n- Active: 196\\n- Screen Failures Cumulative: 58\\n- Withdrawals Cumulative: 14\\n\\n### Sites\\n- Site 01 Enrolled: 21\\n- Site 01 Active: 21\\n- Site 01 Statin Concomitant: 7\\n- Site 02 Enrolled: 16\\n- Site 02 Active: 16\\n- Site 02 Statin Concomitant: 4\\n- Site 03 Enrolled: 19\\n- Site 03 Active: 19\\n- Site 03 Statin Concomitant: 6\\n- Site 04 Enrolled: 14\\n- Site 04 Active: 14\\n- Site 04 Statin Concomitant: 3\\n- Site 05 Enrolled: 17\\n- Site \", \"score\": 0.03177805800756621, \"metadata\": {\"episode_type\": \"signal\", \"phase\": \"root_cause\", \"signal_density\": \"high\"}}, {\"ref_id\": \"clinical_signal_03_ep_018\", \"text\": \"## 2024-07-01 Daily Operations Summary\\n\\n### Enrollment\\n- Total Randomized: 210\\n- Active: 204\\n- Screen Failures Cumulative: 53\\n- Withdrawals Cumulative: 6\\n\\n#### Sites\\n- Site 01 Enrolled: 21\\n- Site 01 Active: 21\\n- Site 01 Statin Concomitant: 7\\n- Site 02 Enrolled: 16\\n- Site 02 Active: 16\\n- Site 02 Statin Concomitant: 4\\n- Site 03 Enrolled: 19\\n- Site 03 Active: 19\\n- Site 03 Statin Concomitant: 5\\n- Site 04 Enrolled: 14\\n- Site 04 Active: 14\\n- Site 04 Statin Concomitant: 4\\n- Site 05 Enrolled: 17\\n- Site \", \"score\": 0.031544957774465976, \"metadata\": {\"episode_type\": \"signal\", \"phase\": \"escalation\", \"signal_density\": \"high\"}}, {\"ref_id\": \"clinical_signal_03_ep_019\", \"text\": \"## 2024-07-08 Daily Operations Summary\\n\\n### Enrollment\\n- Total Randomized: 202\\n- Active: 196\\n- Screen Failures Cumulative: 37\\n- Withdrawals Cumulative: 6\\n\\n### Sites\\n- Site 01\\n  - Enrolled: 20\\n  - Active: 20\\n  - Statin Concomitant: 6\\n- Site 02\\n  - Enrolled: 15\\n  - Active: 15\\n  - Statin Concomitant: 3\\n- Site 03\\n  - Enrolled: 18\\n  - Active: 18\\n  - Statin Concomitant: 5\\n- Site 04\\n  - Enrolled: 13\\n  - Active: 13\\n  - Statin Concomitant: 3\\n- Site 05\\n  - Enrolled: 17\\n  - Active: 17\\n  - Statin Concomitan\", \"score\": 0.03125, \"metadata\": {\"episode_type\": \"signal\", \"phase\": \"escalation\", \"signal_density\": \"high\"}}, {\"ref_id\": \"clinical_signal_03_ep_020\", \"text\": \"## 2024-07-15 Daily Operations Summary\\n\\n### Enrollment\\n- Total Randomized: 216\\n- Active: 206\\n- Screen Failures Cumulative: 45\\n- Withdrawals Cumulative: 10\\n\\n#### Sites\\n- Site 01 Enrolled: 22\\n- Site 01 Active: 22\\n- Site 01 Statin Concomitant: 7\\n- Site 02 Enrolled: 16\\n- Site 02 Active: 16\\n- Site 02 Statin Concomitant: 5\\n- Site 03 Enrolled: 20\\n- Site 03 Active: 20\\n- Site 03 Statin Concomitant: 6\\n- Site 04 Enrolled: 14\\n- Site 04 Active: 14\\n- Site 04 Statin Concomitant: 4\\n- Site 05 Enrolled: 18\\n- Site\", \"score\": 0.030834914611005692, \"metadata\": {\"episode_type\": \"signal\", \"phase\": \"escalation\", \"signal_density\": \"high\"}}, {\"ref_id\": \"clinical_signal_03_ep_022\", \"text\": \"## 2024-07-29 Daily Operations Summary\\n\\n### Enrollment\\n- Total Randomized: 236\\n- Active: 230\\n- Screen Failures Cumulative: 50\\n- Withdrawals Cumulative: 6\\n\\n#### Sites\\n- Site 01\\n  - Enrolled: 24\\n  - Active: 24\\n  - Statin Concomitant: 7\\n- Site 02\\n  - Enrolled: 18\\n  - Active: 18\\n  - Statin Concomitant: 5\\n- Site 03\\n  - Enrolled: 22\\n  - Active: 22\\n  - Statin Concomitant: 7\\n- Site 04\\n  - Enrolled: 16\\n  - Active: 16\\n  - Statin Concomitant: 4\\n- Site 05\\n  - Enrolled: 20\\n  - Active: 20\\n  - Statin Concomita\", \"score\": 0.03007688828584351, \"metadata\": {\"episode_type\": \"signal\", \"phase\": \"escalation\", \"signal_density\": \"high\"}}, {\"ref_id\": \"clinical_signal_03_ep_017\", \"text\": \"## 2024-06-24 Daily Operations Summary\\n\\n### Enrollment\\n- Total Randomized: 225\\n- Active: 214\\n- Screen Failures Cumulative: 30\\n- Withdrawals Cumulative: 11\\n\\n#### Sites\\n- Site 01 Enrolled: 23\\n- Site 01 Active: 23\\n- Site 01 Statin Concomitant: 7\\n- Site 02 Enrolled: 17\\n- Site 02 Active: 17\\n- Site 02 Statin Concomitant: 5\\n- Site 03 Enrolled: 21\\n- Site 03 Active: 21\\n- Site 03 Statin Concomitant: 6\\n- Site 04 Enrolled: 15\\n- Site 04 Active: 15\\n- Site 04 Statin Concomitant: 3\\n- Site 05 Enrolled: 19\\n- Site\", \"score\": 0.029877369007803793, \"metadata\": {\"episode_type\": \"signal\", \"phase\": \"escalation\", \"signal_density\": \"high\"}}]",
              "is_error": false
            }
          ],
          "tokens_used": 0
        },
        {
          "role": "assistant",
          "content": "",
          "tool_calls": [
            {
              "id": "call_06234c06de104e59a9dd4c53",
              "name": "memory_search",
              "arguments": {
                "query": "liver enzyme elevation cause in clinical trial",
                "limit": 7
              }
            }
          ],
          "tokens_used": 3154
        },
        {
          "role": "tool",
          "tool_results": [
            {
              "tool_call_id": "call_06234c06de104e59a9dd4c53",
              "content": "[Context budget exhausted \u2014 synthesize answer from evidence already retrieved]",
              "is_error": false
            }
          ],
          "tokens_used": 0
        },
        {
          "role": "assistant",
          "content": "The provided documents do not contain specific information explaining why liver enzymes are elevated in a subset of trial participants. While several documents mention enrollment data and concomitant statin use across sites [ref_id: clinical_signal_03_ep_021, ref_id: clinical_signal_03_ep_023, ref_id: clinical_signal_03_ep_018], none directly address the underlying cause of elevated liver enzymes. Further investigation or additional data may be required to determine the cause.",
          "tokens_used": 3283
        }
      ],
      "tool_calls_made": 3,
      "total_tokens": 8228,
      "wall_time_ms": 7893.631627084687,
      "budget_violations": [
        "Cumulative result token limit exceeded: 2690 > 2048"
      ],
      "refs_cited": []
    },
    "retrieved_ref_ids": [],
    "valid_ref_ids": []
  },
  {
    "question": {
      "question_id": "cs03_q07_temporal",
      "scope_id": "clinical_signal_03",
      "checkpoint_after": 25,
      "question_type": "temporal",
      "prompt": "When did ALT elevations first become apparent, and how many weeks elapsed before subjects met Hy's Law criteria?",
      "ground_truth": {
        "canonical_answer": "ALT elevations in the statin subgroup first became apparent during the early signal phase. It took approximately 7-13 weeks from initial detection to subjects meeting Hy's Law criteria (ALT >3x ULN + bilirubin >2x ULN) during the escalation phase.",
        "required_evidence_refs": [
          "clinical_signal_03_ep_010",
          "clinical_signal_03_ep_013",
          "clinical_signal_03_ep_017"
        ],
        "key_facts": [
          "ALT elevations are concentrated in subjects receiving concurrent statin therapy, with higher-dose statin subgroups showing proportionally greater enzyme increases",
          "multi-site signal distribution rules out site-specific confounders as causal explanation",
          "ALT elevations appeared progressively over multiple weeks of statin co-administration with onset timing correlating with cumulative exposure duration rather than a single acute event"
        ]
      }
    },
    "answer": {
      "question_id": "cs03_q07_temporal",
      "answer_text": "I cannot determine when ALT elevations first became apparent or how many weeks elapsed before subjects met Hy's Law criteria based on the available information. The search results provided daily operations summaries with enrollment and site data but did not contain details about ALT elevations or Hy's Law criteria. Further targeted information would be required to answer this question.",
      "turns": [
        {
          "role": "assistant",
          "content": "",
          "tool_calls": [
            {
              "id": "call_e56f0f6594c14a53a84cb514",
              "name": "memory_capabilities",
              "arguments": {}
            }
          ],
          "tokens_used": 755
        },
        {
          "role": "tool",
          "tool_results": [
            {
              "tool_call_id": "call_e56f0f6594c14a53a84cb514",
              "content": "{\"search_modes\": [\"keyword\", \"semantic\"], \"filter_fields\": [{\"name\": \"scope_id\", \"field_type\": \"string\", \"description\": \"Filter by scope ID\", \"enum_values\": null}, {\"name\": \"start_date\", \"field_type\": \"string\", \"description\": \"Filter episodes after this ISO date\", \"enum_values\": null}, {\"name\": \"end_date\", \"field_type\": \"string\", \"description\": \"Filter episodes before this ISO date\", \"enum_values\": null}], \"max_results_per_search\": 7, \"supports_date_range\": true, \"extra_tools\": [{\"name\": \"batch_retrieve\", \"description\": \"Retrieve multiple full documents by their reference IDs in a single call. PREFER this over calling memory_retrieve multiple times \\u2014 it is far more efficient and uses only one tool call instead of one per document. After memory_search, pass all ref_ids you want to read to this tool.\", \"parameters\": {\"type\": \"object\", \"properties\": {\"ref_ids\": {\"type\": \"array\", \"items\": {\"type\": \"string\"}, \"description\": \"List of reference IDs to retrieve (from search results).\"}}, \"required\": [\"ref_ids\"]}}]}",
              "is_error": false
            }
          ],
          "tokens_used": 0
        },
        {
          "role": "assistant",
          "content": "",
          "tool_calls": [
            {
              "id": "call_9acf0f0a71df44c5bee58d0f",
              "name": "memory_search",
              "arguments": {
                "query": "ALT elevations Hy's Law criteria timeline",
                "filters": {}
              }
            }
          ],
          "tokens_used": 1056
        },
        {
          "role": "tool",
          "tool_results": [
            {
              "tool_call_id": "call_9acf0f0a71df44c5bee58d0f",
              "content": "[{\"ref_id\": \"clinical_signal_03_ep_020\", \"text\": \"## 2024-07-15 Daily Operations Summary\\n\\n### Enrollment\\n- Total Randomized: 216\\n- Active: 206\\n- Screen Failures Cumulative: 45\\n- Withdrawals Cumulative: 10\\n\\n#### Sites\\n- Site 01 Enrolled: 22\\n- Site 01 Active: 22\\n- Site 01 Statin Concomitant: 7\\n- Site 02 Enrolled: 16\\n- Site 02 Active: 16\\n- Site 02 Statin Concomitant: 5\\n- Site 03 Enrolled: 20\\n- Site 03 Active: 20\\n- Site 03 Statin Concomitant: 6\\n- Site 04 Enrolled: 14\\n- Site 04 Active: 14\\n- Site 04 Statin Concomitant: 4\\n- Site 05 Enrolled: 18\\n- Site\", \"score\": 0.03278688524590164, \"metadata\": {\"episode_type\": \"signal\", \"phase\": \"escalation\", \"signal_density\": \"high\"}}, {\"ref_id\": \"clinical_signal_03_ep_009\", \"text\": \"## 2024-04-29 Daily Operations Summary\\n\\n### Enrollment\\n- Total Randomized: 185\\n- Active: 180\\n- Screen Failures Cumulative: 22\\n- Withdrawals Cumulative: 5\\n\\n#### Sites\\n- Site 01 Enrolled: 18\\n- Site 01 Active: 18\\n- Site 01 Statin Concomitant: 5\\n- Site 02 Enrolled: 14\\n- Site 02 Active: 14\\n- Site 02 Statin Concomitant: 4\\n- Site 03 Enrolled: 17\\n- Site 03 Active: 17\\n- Site 03 Statin Concomitant: 4\\n- Site 04 Enrolled: 12\\n- Site 04 Active: 12\\n- Site 04 Statin Concomitant: 3\\n- Site 05 Enrolled: 15\\n- Site \", \"score\": 0.03149801587301587, \"metadata\": {\"episode_type\": \"signal\", \"phase\": \"early_signal\", \"signal_density\": \"low\"}}, {\"ref_id\": \"clinical_signal_03_ep_013\", \"text\": \"## 2024-05-27 Daily Operations Summary\\n\\n### Enrollment\\n- Total Randomized: 195\\n- Active: 191\\n- Screen Failures Cumulative: 29\\n- Withdrawals Cumulative: 4\\n\\n#### Sites\\n- Site 01\\n  - Enrolled: 19\\n  - Active: 19\\n  - Statin Concomitant: 5\\n- Site 02\\n  - Enrolled: 14\\n  - Active: 14\\n  - Statin Concomitant: 4\\n- Site 03\\n  - Enrolled: 18\\n  - Active: 18\\n  - Statin Concomitant: 5\\n- Site 04\\n  - Enrolled: 13\\n  - Active: 13\\n  - Statin Concomitant: 4\\n- Site 05\\n  - Enrolled: 16\\n  - Active: 16\\n  - Statin Concomita\", \"score\": 0.031024531024531024, \"metadata\": {\"episode_type\": \"signal\", \"phase\": \"early_signal\", \"signal_density\": \"low\"}}, {\"ref_id\": \"clinical_signal_03_ep_011\", \"text\": \"## 2024-05-13 Daily Operations Summary\\n\\n### Enrollment\\n- Total Randomized: 189\\n- Active: 182\\n- Screen Failures Cumulative: 27\\n- Withdrawals Cumulative: 7\\n\\n#### Sites\\n- Site 01\\n  - Enrolled: 19\\n  - Active: 19\\n  - Statin Concomitant: 5\\n- Site 02\\n  - Enrolled: 14\\n  - Active: 14\\n  - Statin Concomitant: 3\\n- Site 03\\n  - Enrolled: 17\\n  - Active: 17\\n  - Statin Concomitant: 5\\n- Site 04\\n  - Enrolled: 12\\n  - Active: 12\\n  - Statin Concomitant: 3\\n- Site 05\\n  - Enrolled: 16\\n  - Active: 16\\n  - Statin Concomita\", \"score\": 0.030834914611005692, \"metadata\": {\"episode_type\": \"signal\", \"phase\": \"early_signal\", \"signal_density\": \"low\"}}, {\"ref_id\": \"clinical_signal_03_ep_010\", \"text\": \"## 2024-05-06 Daily Operations Summary\\n\\n### Enrollment\\n- Total Randomized: 184\\n- Active: 182\\n- Screen Failures Cumulative: 20\\n- Withdrawals Cumulative: 2\\n\\n#### Sites\\n- Site 01 Enrolled: 18\\n- Site 01 Active: 18\\n- Site 01 Statin Concomitant: 5\\n- Site 02 Enrolled: 14\\n- Site 02 Active: 14\\n- Site 02 Statin Concomitant: 3\\n- Site 03 Enrolled: 17\\n- Site 03 Active: 17\\n- Site 03 Statin Concomitant: 4\\n- Site 04 Enrolled: 12\\n- Site 04 Active: 12\\n- Site 04 Statin Concomitant: 3\\n- Site 05 Enrolled: 15\\n- Site \", \"score\": 0.030309988518943745, \"metadata\": {\"episode_type\": \"signal\", \"phase\": \"early_signal\", \"signal_density\": \"low\"}}, {\"ref_id\": \"clinical_signal_03_ep_017\", \"text\": \"## 2024-06-24 Daily Operations Summary\\n\\n### Enrollment\\n- Total Randomized: 225\\n- Active: 214\\n- Screen Failures Cumulative: 30\\n- Withdrawals Cumulative: 11\\n\\n#### Sites\\n- Site 01 Enrolled: 23\\n- Site 01 Active: 23\\n- Site 01 Statin Concomitant: 7\\n- Site 02 Enrolled: 17\\n- Site 02 Active: 17\\n- Site 02 Statin Concomitant: 5\\n- Site 03 Enrolled: 21\\n- Site 03 Active: 21\\n- Site 03 Statin Concomitant: 6\\n- Site 04 Enrolled: 15\\n- Site 04 Active: 15\\n- Site 04 Statin Concomitant: 3\\n- Site 05 Enrolled: 19\\n- Site\", \"score\": 0.030117753623188408, \"metadata\": {\"episode_type\": \"signal\", \"phase\": \"escalation\", \"signal_density\": \"high\"}}, {\"ref_id\": \"clinical_signal_03_ep_018\", \"text\": \"## 2024-07-01 Daily Operations Summary\\n\\n### Enrollment\\n- Total Randomized: 210\\n- Active: 204\\n- Screen Failures Cumulative: 53\\n- Withdrawals Cumulative: 6\\n\\n#### Sites\\n- Site 01 Enrolled: 21\\n- Site 01 Active: 21\\n- Site 01 Statin Concomitant: 7\\n- Site 02 Enrolled: 16\\n- Site 02 Active: 16\\n- Site 02 Statin Concomitant: 4\\n- Site 03 Enrolled: 19\\n- Site 03 Active: 19\\n- Site 03 Statin Concomitant: 5\\n- Site 04 Enrolled: 14\\n- Site 04 Active: 14\\n- Site 04 Statin Concomitant: 4\\n- Site 05 Enrolled: 17\\n- Site \", \"score\": 0.029827662395050816, \"metadata\": {\"episode_type\": \"signal\", \"phase\": \"escalation\", \"signal_density\": \"high\"}}]",
              "is_error": false
            }
          ],
          "tokens_used": 0
        },
        {
          "role": "assistant",
          "content": "",
          "tool_calls": [
            {
              "id": "call_899b810b6e3548139aa128cd",
              "name": "memory_search",
              "arguments": {
                "query": "ALT elevations onset Hy's Law criteria",
                "filters": {}
              }
            }
          ],
          "tokens_used": 3175
        },
        {
          "role": "tool",
          "tool_results": [
            {
              "tool_call_id": "call_899b810b6e3548139aa128cd",
              "content": "[Context budget exhausted \u2014 synthesize answer from evidence already retrieved]",
              "is_error": false
            }
          ],
          "tokens_used": 0
        },
        {
          "role": "assistant",
          "content": "I cannot determine when ALT elevations first became apparent or how many weeks elapsed before subjects met Hy's Law criteria based on the available information. The search results provided daily operations summaries with enrollment and site data but did not contain details about ALT elevations or Hy's Law criteria. Further targeted information would be required to answer this question.",
          "tokens_used": 3267
        }
      ],
      "tool_calls_made": 3,
      "total_tokens": 8253,
      "wall_time_ms": 7737.3374429298565,
      "budget_violations": [
        "Cumulative result token limit exceeded: 2696 > 2048"
      ],
      "refs_cited": []
    },
    "retrieved_ref_ids": [],
    "valid_ref_ids": []
  },
  {
    "question": {
      "question_id": "cs03_q08_counterfactual",
      "scope_id": "clinical_signal_03",
      "checkpoint_after": 25,
      "question_type": "counterfactual",
      "prompt": "If the Site 07 lab equipment calibration issue were responsible for the ALT elevations, what pattern would you expect across sites? Does that match the data?",
      "ground_truth": {
        "canonical_answer": "If Site 07 equipment were the cause, ALT elevations would be confined to Site 07 and resolve after recalibration. Instead, the ALT signal appears across multiple sites and correlates with statin co-administration, not site. The cross-site pattern rules out a site-specific equipment explanation.",
        "required_evidence_refs": [
          "clinical_signal_03_ep_015",
          "clinical_signal_03_ep_018",
          "clinical_signal_03_ep_024"
        ],
        "key_facts": [
          "Site 07 lab equipment issue is not the cause of ALT elevations",
          "multi-site signal distribution rules out site-specific confounders as causal explanation",
          "ALT elevations appeared progressively over multiple weeks of statin co-administration with onset timing correlating with cumulative exposure duration rather than a single acute event"
        ]
      }
    },
    "answer": {
      "question_id": "cs03_q08_counterfactual",
      "answer_text": "The provided search results do not contain information about a calibration issue at Site 07 or its potential impact on ALT elevations. The documents retrieved are daily operations summaries that report enrollment and statin concomitant data by site but do not mention laboratory equipment issues or ALT (alanine aminotransferase) levels [ref_id: clinical_signal_03_ep_015, clinical_signal_03_ep_016, clinical_signal_03_ep_020, clinical_signal_03_ep_005, clinical_signal_03_ep_014, clinical_signal_03_ep_006, clinical_signal_03_ep_018]. \n\nWithout data on ALT elevations or any mention of Site 07's equipment status, it is not possible to determine the expected pattern of ALT elevations if Site 07's calibration were responsible, nor can it be assessed whether such a pattern matches the actual data. Therefore, based on the available information, the question cannot be answered.",
      "turns": [
        {
          "role": "assistant",
          "content": "",
          "tool_calls": [
            {
              "id": "call_f643aef1b78043b8bc157e71",
              "name": "memory_capabilities",
              "arguments": {}
            }
          ],
          "tokens_used": 765
        },
        {
          "role": "tool",
          "tool_results": [
            {
              "tool_call_id": "call_f643aef1b78043b8bc157e71",
              "content": "{\"search_modes\": [\"keyword\", \"semantic\"], \"filter_fields\": [{\"name\": \"scope_id\", \"field_type\": \"string\", \"description\": \"Filter by scope ID\", \"enum_values\": null}, {\"name\": \"start_date\", \"field_type\": \"string\", \"description\": \"Filter episodes after this ISO date\", \"enum_values\": null}, {\"name\": \"end_date\", \"field_type\": \"string\", \"description\": \"Filter episodes before this ISO date\", \"enum_values\": null}], \"max_results_per_search\": 7, \"supports_date_range\": true, \"extra_tools\": [{\"name\": \"batch_retrieve\", \"description\": \"Retrieve multiple full documents by their reference IDs in a single call. PREFER this over calling memory_retrieve multiple times \\u2014 it is far more efficient and uses only one tool call instead of one per document. After memory_search, pass all ref_ids you want to read to this tool.\", \"parameters\": {\"type\": \"object\", \"properties\": {\"ref_ids\": {\"type\": \"array\", \"items\": {\"type\": \"string\"}, \"description\": \"List of reference IDs to retrieve (from search results).\"}}, \"required\": [\"ref_ids\"]}}]}",
              "is_error": false
            }
          ],
          "tokens_used": 0
        },
        {
          "role": "assistant",
          "content": "",
          "tool_calls": [
            {
              "id": "call_5e24d0ca1a9346d8a2134def",
              "name": "memory_search",
              "arguments": {
                "query": "Site 07 lab equipment calibration issue ALT elevations",
                "filters": {}
              }
            }
          ],
          "tokens_used": 1069
        },
        {
          "role": "tool",
          "tool_results": [
            {
              "tool_call_id": "call_5e24d0ca1a9346d8a2134def",
              "content": "[{\"ref_id\": \"clinical_signal_03_ep_015\", \"text\": \"## 2024-06-10 Daily Operations Summary\\n\\n### Enrollment\\n- Total Randomized: 215\\n- Active: 208\\n- Screen Failures Cumulative: 33\\n- Withdrawals Cumulative: 7\\n\\n#### Sites\\n- Site 01 Enrolled: 22\\n- Site 01 Active: 22\\n- Site 01 Statin Concomitant: 5\\n- Site 02 Enrolled: 16\\n- Site 02 Active: 16\\n- Site 02 Statin Concomitant: 4\\n- Site 03 Enrolled: 20\\n- Site 03 Active: 20\\n- Site 03 Statin Concomitant: 5\\n- Site 04 Enrolled: 14\\n- Site 04 Active: 14\\n- Site 04 Statin Concomitant: 3\\n- Site 05 Enrolled: 18\\n- Site \", \"score\": 0.032266458495966696, \"metadata\": {\"episode_type\": \"signal\", \"phase\": \"early_signal\", \"signal_density\": \"low\"}}, {\"ref_id\": \"clinical_signal_03_ep_016\", \"text\": \"## 2024-06-17 Daily Operations Summary\\n\\n### Enrollment\\n- Total Randomized: 204\\n- Active: 198\\n- Screen Failures Cumulative: 47\\n- Withdrawals Cumulative: 6\\n\\n#### Sites\\n- Site 01\\n  - Enrolled: 20\\n  - Active: 20\\n  - Statin Concomitant: 6\\n- Site 02\\n  - Enrolled: 15\\n  - Active: 15\\n  - Statin Concomitant: 4\\n- Site 03\\n  - Enrolled: 19\\n  - Active: 19\\n  - Statin Concomitant: 5\\n- Site 04\\n  - Enrolled: 13\\n  - Active: 13\\n  - Statin Concomitant: 4\\n- Site 05\\n  - Enrolled: 17\\n  - Active: 17\\n  - Statin Concomita\", \"score\": 0.03177805800756621, \"metadata\": {\"episode_type\": \"signal\", \"phase\": \"red_herring\", \"signal_density\": \"medium\"}}, {\"ref_id\": \"clinical_signal_03_ep_020\", \"text\": \"## 2024-07-15 Daily Operations Summary\\n\\n### Enrollment\\n- Total Randomized: 216\\n- Active: 206\\n- Screen Failures Cumulative: 45\\n- Withdrawals Cumulative: 10\\n\\n#### Sites\\n- Site 01 Enrolled: 22\\n- Site 01 Active: 22\\n- Site 01 Statin Concomitant: 7\\n- Site 02 Enrolled: 16\\n- Site 02 Active: 16\\n- Site 02 Statin Concomitant: 5\\n- Site 03 Enrolled: 20\\n- Site 03 Active: 20\\n- Site 03 Statin Concomitant: 6\\n- Site 04 Enrolled: 14\\n- Site 04 Active: 14\\n- Site 04 Statin Concomitant: 4\\n- Site 05 Enrolled: 18\\n- Site\", \"score\": 0.0315136476426799, \"metadata\": {\"episode_type\": \"signal\", \"phase\": \"escalation\", \"signal_density\": \"high\"}}, {\"ref_id\": \"clinical_signal_03_ep_005\", \"text\": \"## 2024-04-01 Daily Operations Summary\\n\\n### Enrollment\\n- Total Randomized: 120\\n- Active: 118\\n- Screen Failures Cumulative: 11\\n- Withdrawals Cumulative: 2\\n\\n#### Sites\\n- Site 01 Enrolled: 12\\n- Site 01 Active: 12\\n- Site 01 Statin Concomitant: 4\\n- Site 02 Enrolled: 9\\n- Site 02 Active: 9\\n- Site 02 Statin Concomitant: 3\\n- Site 03 Enrolled: 11\\n- Site 03 Active: 11\\n- Site 03 Statin Concomitant: 3\\n- Site 04 Enrolled: 8\\n- Site 04 Active: 8\\n- Site 04 Statin Concomitant: 2\\n- Site 05 Enrolled: 10\\n- Site 05 A\", \"score\": 0.031054405392392875, \"metadata\": {\"episode_type\": \"signal\", \"phase\": \"baseline\", \"signal_density\": \"none\"}}, {\"ref_id\": \"clinical_signal_03_ep_014\", \"text\": \"## 2024-06-03 Daily Operations Summary\\n\\n### Enrollment\\n- Total Randomized: 192\\n- Active: 182\\n- Screen Failures Cumulative: 28\\n- Withdrawals Cumulative: 10\\n\\n#### Sites\\n- Site 01 Enrolled: 19\\n- Site 01 Active: 19\\n- Site 01 Statin Concomitant: 5\\n- Site 02 Enrolled: 14\\n- Site 02 Active: 14\\n- Site 02 Statin Concomitant: 4\\n- Site 03 Enrolled: 18\\n- Site 03 Active: 18\\n- Site 03 Statin Concomitant: 4\\n- Site 04 Enrolled: 13\\n- Site 04 Active: 13\\n- Site 04 Statin Concomitant: 3\\n- Site 05 Enrolled: 16\\n- Site\", \"score\": 0.031024531024531024, \"metadata\": {\"episode_type\": \"signal\", \"phase\": \"early_signal\", \"signal_density\": \"low\"}}, {\"ref_id\": \"clinical_signal_03_ep_006\", \"text\": \"## 2024-04-08 Daily Operations Summary\\n\\n### Enrollment\\n- Total Randomized: 140\\n- Active: 137\\n- Screen Failures Cumulative: 11\\n- Withdrawals Cumulative: 3\\n\\n#### Sites\\n- Site 01 Enrolled: 14\\n- Site 01 Active: 14\\n- Site 01 Statin Concomitant: 4\\n- Site 02 Enrolled: 10\\n- Site 02 Active: 10\\n- Site 02 Statin Concomitant: 3\\n- Site 03 Enrolled: 18\\n- Site 03 Active: 17\\n- Site 03 Statin Concomitant: 5\\n- Site 04 Enrolled: 9\\n- Site 04 Active: 9\\n- Site 04 Statin Concomitant: 2\\n- Site 05 Enrolled: 11\\n- Site 05\", \"score\": 0.02900988017658188, \"metadata\": {\"episode_type\": \"signal\", \"phase\": \"baseline\", \"signal_density\": \"none\"}}, {\"ref_id\": \"clinical_signal_03_ep_018\", \"text\": \"## 2024-07-01 Daily Operations Summary\\n\\n### Enrollment\\n- Total Randomized: 210\\n- Active: 204\\n- Screen Failures Cumulative: 53\\n- Withdrawals Cumulative: 6\\n\\n#### Sites\\n- Site 01 Enrolled: 21\\n- Site 01 Active: 21\\n- Site 01 Statin Concomitant: 7\\n- Site 02 Enrolled: 16\\n- Site 02 Active: 16\\n- Site 02 Statin Concomitant: 4\\n- Site 03 Enrolled: 19\\n- Site 03 Active: 19\\n- Site 03 Statin Concomitant: 5\\n- Site 04 Enrolled: 14\\n- Site 04 Active: 14\\n- Site 04 Statin Concomitant: 4\\n- Site 05 Enrolled: 17\\n- Site \", \"score\": 0.028991596638655463, \"metadata\": {\"episode_type\": \"signal\", \"phase\": \"escalation\", \"signal_density\": \"high\"}}]",
              "is_error": false
            }
          ],
          "tokens_used": 0
        },
        {
          "role": "assistant",
          "content": "",
          "tool_calls": [
            {
              "id": "call_0dfc4163bb44403eb5008041",
              "name": "memory_search",
              "arguments": {
                "query": "ALT elevations across sites Site 07 calibration issue",
                "filters": {}
              }
            }
          ],
          "tokens_used": 3185
        },
        {
          "role": "tool",
          "tool_results": [
            {
              "tool_call_id": "call_0dfc4163bb44403eb5008041",
              "content": "[Context budget exhausted \u2014 synthesize answer from evidence already retrieved]",
              "is_error": false
            }
          ],
          "tokens_used": 0
        },
        {
          "role": "assistant",
          "content": "The provided search results do not contain information about a calibration issue at Site 07 or its potential impact on ALT elevations. The documents retrieved are daily operations summaries that report enrollment and statin concomitant data by site but do not mention laboratory equipment issues or ALT (alanine aminotransferase) levels [ref_id: clinical_signal_03_ep_015, clinical_signal_03_ep_016, clinical_signal_03_ep_020, clinical_signal_03_ep_005, clinical_signal_03_ep_014, clinical_signal_03_ep_006, clinical_signal_03_ep_018]. \n\nWithout data on ALT elevations or any mention of Site 07's equipment status, it is not possible to determine the expected pattern of ALT elevations if Site 07's calibration were responsible, nor can it be assessed whether such a pattern matches the actual data. Therefore, based on the available information, the question cannot be answered.",
          "tokens_used": 3427
        }
      ],
      "tool_calls_made": 3,
      "total_tokens": 8446,
      "wall_time_ms": 12782.026011962444,
      "budget_violations": [
        "Cumulative result token limit exceeded: 2693 > 2048"
      ],
      "refs_cited": []
    },
    "retrieved_ref_ids": [],
    "valid_ref_ids": []
  },
  {
    "question": {
      "question_id": "cs03_q14_paraphrase",
      "scope_id": "clinical_signal_03",
      "checkpoint_after": 25,
      "question_type": "paraphrase",
      "prompt": "Why is there a difference in liver enzyme levels between patient subgroups?",
      "ground_truth": {
        "canonical_answer": "A drug-drug interaction between LNS-4821 and concomitant statin therapy via CYP3A4 inhibition causes hepatotoxicity in the statin subgroup. The signal appears across all sites, not just Site 07, ruling out the equipment calibration hypothesis.",
        "required_evidence_refs": [
          "clinical_signal_03_ep_010",
          "clinical_signal_03_ep_018",
          "clinical_signal_03_ep_023",
          "clinical_signal_03_ep_015"
        ],
        "key_facts": [
          "ALT elevations are concentrated in subjects receiving concurrent statin therapy, with higher-dose statin subgroups showing proportionally greater enzyme increases",
          "multi-site signal distribution rules out site-specific confounders as causal explanation",
          "the hepatic enzyme pattern is consistent with a drug-drug interaction mediated through shared hepatic metabolism pathways, not direct hepatotoxicity",
          "Site 07 lab equipment issue is not the cause of ALT elevations"
        ]
      }
    },
    "answer": {
      "question_id": "cs03_q14_paraphrase",
      "answer_text": "The difference in liver enzyme levels between patient subgroups appears to be primarily associated with the use of statins as a concomitant medication. In the statin subgroup, liver enzyme levels such as ALT and AST show a notable increase over time compared to baseline values.\n\nAt baseline (March 2024), the statin subgroup had relatively normal liver enzyme levels, with ALT means of 26.8 U/L and 26.0 U/L across two early reports [clinical_signal_03_ep_002][clinical_signal_03_ep_003]. However, by July and August 2024, there was a significant rise in these enzymes: ALT mean increased to 90.2 U/L on July 1 [clinical_signal_03_ep_018], further rising to 103.2 U/L on July 8 [clinical_signal_03_ep_019], and reaching 133.5 U/L by August 12 [clinical_signal_03_ep_024]. Similarly, AST levels followed this upward trend, increasing from 22.1 U/L at baseline to 98.1 U/L in the latest assessment [clinical_signal_03_ep_002][clinical_signal_03_ep_024].\n\nThis progressive elevation in liver enzymes\u2014particularly ALT and AST\u2014suggests that patients taking statins may be experiencing drug-induced liver injury or an additive hepatotoxic effect when combined with the investigational treatment. The consistent rise across multiple time points and the absence of similar trends in non-statin subgroups (not retrieved but implied by focus on statin subgroup) supports this conclusion [clinical_signal_03_ep_018][clinical_signal_03_ep_019][clinical_signal_03_ep_024].",
      "turns": [
        {
          "role": "assistant",
          "content": "",
          "tool_calls": [
            {
              "id": "call_902be3c97b204b478502a598",
              "name": "memory_capabilities",
              "arguments": {}
            }
          ],
          "tokens_used": 747
        },
        {
          "role": "tool",
          "tool_results": [
            {
              "tool_call_id": "call_902be3c97b204b478502a598",
              "content": "{\"search_modes\": [\"keyword\", \"semantic\"], \"filter_fields\": [{\"name\": \"scope_id\", \"field_type\": \"string\", \"description\": \"Filter by scope ID\", \"enum_values\": null}, {\"name\": \"start_date\", \"field_type\": \"string\", \"description\": \"Filter episodes after this ISO date\", \"enum_values\": null}, {\"name\": \"end_date\", \"field_type\": \"string\", \"description\": \"Filter episodes before this ISO date\", \"enum_values\": null}], \"max_results_per_search\": 7, \"supports_date_range\": true, \"extra_tools\": [{\"name\": \"batch_retrieve\", \"description\": \"Retrieve multiple full documents by their reference IDs in a single call. PREFER this over calling memory_retrieve multiple times \\u2014 it is far more efficient and uses only one tool call instead of one per document. After memory_search, pass all ref_ids you want to read to this tool.\", \"parameters\": {\"type\": \"object\", \"properties\": {\"ref_ids\": {\"type\": \"array\", \"items\": {\"type\": \"string\"}, \"description\": \"List of reference IDs to retrieve (from search results).\"}}, \"required\": [\"ref_ids\"]}}]}",
              "is_error": false
            }
          ],
          "tokens_used": 0
        },
        {
          "role": "assistant",
          "content": "",
          "tool_calls": [
            {
              "id": "call_f4304dd3e38946da9ddcec3a",
              "name": "memory_search",
              "arguments": {
                "query": "difference in liver enzyme levels between patient subgroups",
                "limit": 7
              }
            }
          ],
          "tokens_used": 1049
        },
        {
          "role": "tool",
          "tool_results": [
            {
              "tool_call_id": "call_f4304dd3e38946da9ddcec3a",
              "content": "[{\"ref_id\": \"clinical_signal_03_ep_023\", \"text\": \"## 2024-08-05 Daily Operations Summary\\n\\n### Enrollment\\n- Total Randomized: 210\\n- Active: 196\\n- Screen Failures Cumulative: 58\\n- Withdrawals Cumulative: 14\\n\\n### Sites\\n- Site 01 Enrolled: 21\\n- Site 01 Active: 21\\n- Site 01 Statin Concomitant: 7\\n- Site 02 Enrolled: 16\\n- Site 02 Active: 16\\n- Site 02 Statin Concomitant: 4\\n- Site 03 Enrolled: 19\\n- Site 03 Active: 19\\n- Site 03 Statin Concomitant: 6\\n- Site 04 Enrolled: 14\\n- Site 04 Active: 14\\n- Site 04 Statin Concomitant: 3\\n- Site 05 Enrolled: 17\\n- Site \", \"score\": 0.031754032258064516, \"metadata\": {\"episode_type\": \"signal\", \"phase\": \"root_cause\", \"signal_density\": \"high\"}}, {\"ref_id\": \"clinical_signal_03_ep_002\", \"text\": \"## 2024-03-11 Daily Operations Summary\\n### Lab Panels\\n- Statin Subgroup N: 53\\n- Statin Subgroup ALT (U/L) Mean: 26.8\\n- Statin Subgroup ALT (U/L) Median: 26.3\\n- Statin Subgroup AST (U/L) Mean: 22.1\\n- Statin Subgroup AST (U/L) Median: 20.8\\n- Statin Subgroup Bilirubin (mg/dL) Mean: 0.73\\n- Statin Subgroup Bilirubin (mg/dL) Median: 0.72\\n- Statin Subgroup ALP (U/L) Mean: 71.0\\n- Statin Subgroup ALP (U/L) Median: 75.0\\n- Statin Subgroup Creatinine (mg/dL) Mean: 0.85\\n- Statin Subgroup Creatinine (mg/dL) M\", \"score\": 0.03131881575727918, \"metadata\": {\"episode_type\": \"signal\", \"phase\": \"baseline\", \"signal_density\": \"none\"}}, {\"ref_id\": \"clinical_signal_03_ep_003\", \"text\": \"## 2024-03-18 Daily Operations Summary\\n### Lab Panels\\n- Statin Subgroup N: 55\\n- Statin Subgroup ALT (U/L) Mean: 26.0\\n- Statin Subgroup ALT (U/L) Median: 24.3\\n- Statin Subgroup AST (U/L) Mean: 27.9\\n- Statin Subgroup AST (U/L) Median: 25.9\\n- Statin Subgroup Bilirubin (mg/dL) Mean: 0.59\\n- Statin Subgroup Bilirubin (mg/dL) Median: 0.56\\n- Statin Subgroup ALP (U/L) Mean: 79.3\\n- Statin Subgroup ALP (U/L) Median: 57.2\\n- Statin Subgroup Creatinine (mg/dL) Mean: 1.04\\n- Statin Subgroup Creatinine (mg/dL) M\", \"score\": 0.031054405392392875, \"metadata\": {\"episode_type\": \"signal\", \"phase\": \"baseline\", \"signal_density\": \"none\"}}, {\"ref_id\": \"clinical_signal_03_ep_022\", \"text\": \"## 2024-07-29 Daily Operations Summary\\n\\n### Enrollment\\n- Total Randomized: 236\\n- Active: 230\\n- Screen Failures Cumulative: 50\\n- Withdrawals Cumulative: 6\\n\\n#### Sites\\n- Site 01\\n  - Enrolled: 24\\n  - Active: 24\\n  - Statin Concomitant: 7\\n- Site 02\\n  - Enrolled: 18\\n  - Active: 18\\n  - Statin Concomitant: 5\\n- Site 03\\n  - Enrolled: 22\\n  - Active: 22\\n  - Statin Concomitant: 7\\n- Site 04\\n  - Enrolled: 16\\n  - Active: 16\\n  - Statin Concomitant: 4\\n- Site 05\\n  - Enrolled: 20\\n  - Active: 20\\n  - Statin Concomita\", \"score\": 0.030886196246139225, \"metadata\": {\"episode_type\": \"signal\", \"phase\": \"escalation\", \"signal_density\": \"high\"}}, {\"ref_id\": \"clinical_signal_03_ep_018\", \"text\": \"## 2024-07-01 Daily Operations Summary\\n### Lab Panels\\n- Statin Subgroup N: 53\\n- Statin Subgroup ALT Mean (U/L): 90.2\\n- Statin Subgroup ALT Median (U/L): 88.7\\n- Statin Subgroup AST Mean (U/L): 69.2\\n- Statin Subgroup AST Median (U/L): 69.1\\n- Statin Subgroup Bilirubin Mean (mg/dL): 1.44\\n- Statin Subgroup Bilirubin Median (mg/dL): 1.43\\n- Statin Subgroup ALP Mean (U/L): 83.4\\n- Statin Subgroup ALP Median (U/L): 76.7\\n- Statin Subgroup Creatinine Mean (mg/dL): 0.85\\n- Statin Subgroup Creatinine Median (m\", \"score\": 0.030798389007344232, \"metadata\": {\"episode_type\": \"signal\", \"phase\": \"escalation\", \"signal_density\": \"high\"}}, {\"ref_id\": \"clinical_signal_03_ep_019\", \"text\": \"## 2024-07-08 Daily Operations Summary\\n### Lab Panels\\n- Statin Subgroup\\n  - N: 54\\n  - ALT (U/L) Mean: 103.2\\n  - ALT (U/L) Median: 100.3\\n  - AST (U/L) Mean: 73.7\\n  - AST (U/L) Median: 73.6\\n  - Bilirubin (mg/dL) Mean: 1.56\\n  - Bilirubin (mg/dL) Median: 1.53\\n  - ALP (U/L) Mean: 74.1\\n  - ALP (U/L) Median: 69.1\\n  - Creatinine (mg/dL) Mean: 0.82\\n  - Creatinine (mg/dL) Median: 0.95\\n  - BUN (mg/dL) Mean: 13.4\\n  - BUN (mg/dL) Median: 13.0\\n  - WBC (K) Mean: 7.8\\n  - WBC (K) Median: 5.9\\n  - Platelets (K) Me\", \"score\": 0.030309988518943745, \"metadata\": {\"episode_type\": \"signal\", \"phase\": \"escalation\", \"signal_density\": \"high\"}}, {\"ref_id\": \"clinical_signal_03_ep_024\", \"text\": \"## 2024-08-12 Daily Operations Summary\\n### Lab Panels\\n- Statin Subgroup\\n  - N: 53\\n  - ALT (U/L) Mean: 133.5\\n  - ALT (U/L) Median: 131.2\\n  - AST (U/L) Mean: 98.1\\n  - AST (U/L) Median: 96.3\\n  - Bilirubin (mg/dL) Mean: 2.08\\n  - Bilirubin (mg/dL) Median: 2.05\\n  - ALP (U/L) Mean: 71.4\\n  - ALP (U/L) Median: 70.4\\n  - Creatinine (mg/dL) Mean: 0.97\\n  - Creatinine (mg/dL) Median: 0.9\\n  - BUN (mg/dL) Mean: 16.8\\n  - BUN (mg/dL) Median: 16.2\\n  - WBC (K) Mean: 6.9\\n  - WBC (K) Median: 7.4\\n  - Platelets (K) Mea\", \"score\": 0.03007688828584351, \"metadata\": {\"episode_type\": \"signal\", \"phase\": \"root_cause\", \"signal_density\": \"high\"}}]",
              "is_error": false
            }
          ],
          "tokens_used": 0
        },
        {
          "role": "assistant",
          "content": "",
          "tool_calls": [
            {
              "id": "call_f4a2abc8ca5242b49387a195",
              "name": "batch_retrieve",
              "arguments": {
                "ref_ids": [
                  "clinical_signal_03_ep_002",
                  "clinical_signal_03_ep_003",
                  "clinical_signal_03_ep_018",
                  "clinical_signal_03_ep_019",
                  "clinical_signal_03_ep_024"
                ]
              }
            }
          ],
          "tokens_used": 3272
        },
        {
          "role": "tool",
          "tool_results": [
            {
              "tool_call_id": "call_f4a2abc8ca5242b49387a195",
              "content": "[Context budget exhausted \u2014 synthesize answer from evidence already retrieved]",
              "is_error": false
            }
          ],
          "tokens_used": 0
        },
        {
          "role": "assistant",
          "content": "The difference in liver enzyme levels between patient subgroups appears to be primarily associated with the use of statins as a concomitant medication. In the statin subgroup, liver enzyme levels such as ALT and AST show a notable increase over time compared to baseline values.\n\nAt baseline (March 2024), the statin subgroup had relatively normal liver enzyme levels, with ALT means of 26.8 U/L and 26.0 U/L across two early reports [clinical_signal_03_ep_002][clinical_signal_03_ep_003]. However, by July and August 2024, there was a significant rise in these enzymes: ALT mean increased to 90.2 U/L on July 1 [clinical_signal_03_ep_018], further rising to 103.2 U/L on July 8 [clinical_signal_03_ep_019], and reaching 133.5 U/L by August 12 [clinical_signal_03_ep_024]. Similarly, AST levels followed this upward trend, increasing from 22.1 U/L at baseline to 98.1 U/L in the latest assessment [clinical_signal_03_ep_002][clinical_signal_03_ep_024].\n\nThis progressive elevation in liver enzymes\u2014particularly ALT and AST\u2014suggests that patients taking statins may be experiencing drug-induced liver injury or an additive hepatotoxic effect when combined with the investigational treatment. The consistent rise across multiple time points and the absence of similar trends in non-statin subgroups (not retrieved but implied by focus on statin subgroup) supports this conclusion [clinical_signal_03_ep_018][clinical_signal_03_ep_019][clinical_signal_03_ep_024].",
          "tokens_used": 3683
        }
      ],
      "tool_calls_made": 3,
      "total_tokens": 8751,
      "wall_time_ms": 23301.135380053893,
      "budget_violations": [
        "Cumulative result token limit exceeded: 6688 > 2048"
      ],
      "refs_cited": [
        "clinical_signal_03_ep_002",
        "clinical_signal_03_ep_003",
        "clinical_signal_03_ep_018",
        "clinical_signal_03_ep_019",
        "clinical_signal_03_ep_024"
      ]
    },
    "retrieved_ref_ids": [
      "clinical_signal_03_ep_002",
      "clinical_signal_03_ep_003",
      "clinical_signal_03_ep_018",
      "clinical_signal_03_ep_019",
      "clinical_signal_03_ep_024"
    ],
    "valid_ref_ids": [
      "clinical_signal_03_ep_002",
      "clinical_signal_03_ep_003",
      "clinical_signal_03_ep_018",
      "clinical_signal_03_ep_019",
      "clinical_signal_03_ep_024"
    ]
  },
  {
    "question": {
      "question_id": "cs03_q16_negative",
      "scope_id": "clinical_signal_03",
      "checkpoint_after": 25,
      "question_type": "negative",
      "prompt": "Are there musculoskeletal or pain-related adverse events associated with LNS-4821?",
      "ground_truth": {
        "canonical_answer": "No. Pain and musculoskeletal endpoints show no drug-related adverse trends. The safety signal is hepatic, confined to the statin co-administered subgroup.",
        "required_evidence_refs": [
          "clinical_signal_03_ep_006",
          "clinical_signal_03_ep_013"
        ],
        "key_facts": [
          "musculoskeletal safety endpoints track within expected ranges, confirming the safety signal is organ-specific to the liver",
          "ALT elevations are concentrated in subjects receiving concurrent statin therapy, with higher-dose statin subgroups showing proportionally greater enzyme increases"
        ]
      }
    },
    "answer": {
      "question_id": "cs03_q16_negative",
      "answer_text": "Based on the available information, there is no direct mention of musculoskeletal or pain-related adverse events specifically associated with LNS-4821. The documented adverse events include fatigue and headache, both of which were reported as grade 1 and either possibly or unlikely related to the treatment [clinical_signal_03_ep_003]. No episodes retrieved from the memory system reference musculoskeletal symptoms or pain-related events in the context of LNS-4821 administration. Therefore, within the current data, such adverse events are not reported.",
      "turns": [
        {
          "role": "assistant",
          "content": "",
          "tool_calls": [
            {
              "id": "call_3c0896dbfd934da6b619b43d",
              "name": "memory_search",
              "arguments": {
                "query": "LNS-4821 musculoskeletal adverse events",
                "limit": 5
              }
            }
          ],
          "tokens_used": 774
        },
        {
          "role": "tool",
          "tool_results": [
            {
              "tool_call_id": "call_3c0896dbfd934da6b619b43d",
              "content": "[{\"ref_id\": \"clinical_signal_03_ep_020\", \"text\": \"## 2024-07-15 Daily Operations Summary\\n\\n### Enrollment\\n- Total Randomized: 216\\n- Active: 206\\n- Screen Failures Cumulative: 45\\n- Withdrawals Cumulative: 10\\n\\n#### Sites\\n- Site 01 Enrolled: 22\\n- Site 01 Active: 22\\n- Site 01 Statin Concomitant: 7\\n- Site 02 Enrolled: 16\\n- Site 02 Active: 16\\n- Site 02 Statin Concomitant: 5\\n- Site 03 Enrolled: 20\\n- Site 03 Active: 20\\n- Site 03 Statin Concomitant: 6\\n- Site 04 Enrolled: 14\\n- Site 04 Active: 14\\n- Site 04 Statin Concomitant: 4\\n- Site 05 Enrolled: 18\\n- Site\", \"score\": 0.030679156908665108, \"metadata\": {\"episode_type\": \"signal\", \"phase\": \"escalation\", \"signal_density\": \"high\"}}, {\"ref_id\": \"clinical_signal_03_ep_004\", \"text\": \"## 2024-03-25 Daily Operations Summary\\n\\n### Enrollment\\n- Total Randomized: 100\\n- Active: 98\\n- Screen Failures Cumulative: 11\\n- Withdrawals Cumulative: 2\\n\\n#### Sites\\n- Site 01\\n  - Enrolled: 10\\n  - Active: 10\\n  - Statin Concomitant: 2\\n- Site 02\\n  - Enrolled: 7\\n  - Active: 7\\n  - Statin Concomitant: 1\\n- Site 03\\n  - Enrolled: 9\\n  - Active: 9\\n  - Statin Concomitant: 2\\n- Site 04\\n  - Enrolled: 6\\n  - Active: 6\\n  - Statin Concomitant: 1\\n- Site 05\\n  - Enrolled: 8\\n  - Active: 8\\n  - Statin Concomitant: 2\\n- S\", \"score\": 0.030309988518943745, \"metadata\": {\"episode_type\": \"signal\", \"phase\": \"baseline\", \"signal_density\": \"none\"}}, {\"ref_id\": \"clinical_signal_03_ep_023\", \"text\": \"## 2024-08-05 Daily Operations Summary\\n\\n### Enrollment\\n- Total Randomized: 210\\n- Active: 196\\n- Screen Failures Cumulative: 58\\n- Withdrawals Cumulative: 14\\n\\n### Sites\\n- Site 01 Enrolled: 21\\n- Site 01 Active: 21\\n- Site 01 Statin Concomitant: 7\\n- Site 02 Enrolled: 16\\n- Site 02 Active: 16\\n- Site 02 Statin Concomitant: 4\\n- Site 03 Enrolled: 19\\n- Site 03 Active: 19\\n- Site 03 Statin Concomitant: 6\\n- Site 04 Enrolled: 14\\n- Site 04 Active: 14\\n- Site 04 Statin Concomitant: 3\\n- Site 05 Enrolled: 17\\n- Site \", \"score\": 0.02976190476190476, \"metadata\": {\"episode_type\": \"signal\", \"phase\": \"root_cause\", \"signal_density\": \"high\"}}, {\"ref_id\": \"clinical_signal_03_ep_003\", \"text\": \"## 2024-03-18 Daily Operations Summary\\n### Adverse Events\\n- AE ID: AE-0008, Description: fatigue, Grade: 1, Relatedness: unlikely related, Resolved: true, Subject Group: non_statin\\n- AE ID: AE-0009, Description: headache, Grade: 1, Relatedness: possibly related, Resolved: true, Subject Group: non_statin\\n- AE ID: AE-0010, Description: fatigue, Grade: 1, Relatedness: unlikely related, Resolved: true, Subject Group: statin\", \"score\": 0.029551337359792925, \"metadata\": {\"episode_type\": \"signal\", \"phase\": \"baseline\", \"signal_density\": \"none\"}}, {\"ref_id\": \"clinical_signal_03_ep_025\", \"text\": \"## 2024-08-19 Daily Operations Summary\\n\\n### Enrollment\\n- Total Randomized: 231\\n- Active: 216\\n- Screen Failures Cumulative: 42\\n- Withdrawals Cumulative: 15\\n\\n#### Sites\\n- Site 01 Enrolled: 23\\n- Site 01 Active: 22\\n- Site 01 Statin Concomitant: 6\\n- Site 02 Enrolled: 17\\n- Site 02 Active: 16\\n- Site 02 Statin Concomitant: 5\\n- Site 03 Enrolled: 21\\n- Site 03 Active: 21\\n- Site 03 Statin Concomitant: 6\\n- Site 04 Enrolled: 15\\n- Site 04 Active: 14\\n- Site 04 Statin Concomitant: 5\\n- Site 05 Enrolled: 19\\n- Site\", \"score\": 0.02928692699490662, \"metadata\": {\"episode_type\": \"signal\", \"phase\": \"root_cause\", \"signal_density\": \"high\"}}]",
              "is_error": false
            }
          ],
          "tokens_used": 0
        },
        {
          "role": "assistant",
          "content": "",
          "tool_calls": [
            {
              "id": "call_ee4255e9b55844d5b6053970",
              "name": "memory_search",
              "arguments": {
                "query": "LNS-4821 pain-related adverse events",
                "limit": 5
              }
            }
          ],
          "tokens_used": 2209
        },
        {
          "role": "tool",
          "tool_results": [
            {
              "tool_call_id": "call_ee4255e9b55844d5b6053970",
              "content": "[{\"ref_id\": \"clinical_signal_03_ep_020\", \"text\": \"## 2024-07-15 Daily Operations Summary\\n\\n### Enrollment\\n- Total Randomized: 216\\n- Active: 206\\n- Screen Failures Cumulative: 45\\n- Withdrawals Cumulative: 10\\n\\n#### Sites\\n- Site 01 Enrolled: 22\\n- Site 01 Active: 22\\n- Site 01 Statin Concomitant: 7\\n- Site 02 Enrolled: 16\\n- Site 02 Active: 16\\n- Site 02 Statin Concomitant: 5\\n- Site 03 Enrolled: 20\\n- Site 03 Active: 20\\n- Site 03 Statin Concomitant: 6\\n- Site 04 Enrolled: 14\\n- Site 04 Active: 14\\n- Site 04 Statin Concomitant: 4\\n- Site 05 Enrolled: 18\\n- Site\", \"score\": 0.03177805800756621, \"metadata\": {\"episode_type\": \"signal\", \"phase\": \"escalation\", \"signal_density\": \"high\"}}, {\"ref_id\": \"clinical_signal_03_ep_023\", \"text\": \"## 2024-08-05 Daily Operations Summary\\n\\n### Enrollment\\n- Total Randomized: 210\\n- Active: 196\\n- Screen Failures Cumulative: 58\\n- Withdrawals Cumulative: 14\\n\\n### Sites\\n- Site 01 Enrolled: 21\\n- Site 01 Active: 21\\n- Site 01 Statin Concomitant: 7\\n- Site 02 Enrolled: 16\\n- Site 02 Active: 16\\n- Site 02 Statin Concomitant: 4\\n- Site 03 Enrolled: 19\\n- Site 03 Active: 19\\n- Site 03 Statin Concomitant: 6\\n- Site 04 Enrolled: 14\\n- Site 04 Active: 14\\n- Site 04 Statin Concomitant: 3\\n- Site 05 Enrolled: 17\\n- Site \", \"score\": 0.03057889822595705, \"metadata\": {\"episode_type\": \"signal\", \"phase\": \"root_cause\", \"signal_density\": \"high\"}}, {\"ref_id\": \"clinical_signal_03_ep_019\", \"text\": \"## 2024-07-08 Daily Operations Summary\\n\\n### Enrollment\\n- Total Randomized: 202\\n- Active: 196\\n- Screen Failures Cumulative: 37\\n- Withdrawals Cumulative: 6\\n\\n### Sites\\n- Site 01\\n  - Enrolled: 20\\n  - Active: 20\\n  - Statin Concomitant: 6\\n- Site 02\\n  - Enrolled: 15\\n  - Active: 15\\n  - Statin Concomitant: 3\\n- Site 03\\n  - Enrolled: 18\\n  - Active: 18\\n  - Statin Concomitant: 5\\n- Site 04\\n  - Enrolled: 13\\n  - Active: 13\\n  - Statin Concomitant: 3\\n- Site 05\\n  - Enrolled: 17\\n  - Active: 17\\n  - Statin Concomitan\", \"score\": 0.029910714285714284, \"metadata\": {\"episode_type\": \"signal\", \"phase\": \"escalation\", \"signal_density\": \"high\"}}, {\"ref_id\": \"clinical_signal_03_ep_004\", \"text\": \"## 2024-03-25 Daily Operations Summary\\n\\n### Enrollment\\n- Total Randomized: 100\\n- Active: 98\\n- Screen Failures Cumulative: 11\\n- Withdrawals Cumulative: 2\\n\\n#### Sites\\n- Site 01\\n  - Enrolled: 10\\n  - Active: 10\\n  - Statin Concomitant: 2\\n- Site 02\\n  - Enrolled: 7\\n  - Active: 7\\n  - Statin Concomitant: 1\\n- Site 03\\n  - Enrolled: 9\\n  - Active: 9\\n  - Statin Concomitant: 2\\n- Site 04\\n  - Enrolled: 6\\n  - Active: 6\\n  - Statin Concomitant: 1\\n- Site 05\\n  - Enrolled: 8\\n  - Active: 8\\n  - Statin Concomitant: 2\\n- S\", \"score\": 0.029877369007803793, \"metadata\": {\"episode_type\": \"signal\", \"phase\": \"baseline\", \"signal_density\": \"none\"}}, {\"ref_id\": \"clinical_signal_03_ep_003\", \"text\": \"## 2024-03-18 Daily Operations Summary\\n### Adverse Events\\n- AE ID: AE-0008, Description: fatigue, Grade: 1, Relatedness: unlikely related, Resolved: true, Subject Group: non_statin\\n- AE ID: AE-0009, Description: headache, Grade: 1, Relatedness: possibly related, Resolved: true, Subject Group: non_statin\\n- AE ID: AE-0010, Description: fatigue, Grade: 1, Relatedness: unlikely related, Resolved: true, Subject Group: statin\", \"score\": 0.029551337359792925, \"metadata\": {\"episode_type\": \"signal\", \"phase\": \"baseline\", \"signal_density\": \"none\"}}]",
              "is_error": false
            }
          ],
          "tokens_used": 0
        },
        {
          "role": "assistant",
          "content": "",
          "tool_calls": [
            {
              "id": "call_9caedde3a8a348f8bbe11ae0",
              "name": "memory_search",
              "arguments": {
                "query": "LNS-4821 adverse events",
                "limit": 10
              }
            }
          ],
          "tokens_used": 3645
        },
        {
          "role": "tool",
          "tool_results": [
            {
              "tool_call_id": "call_9caedde3a8a348f8bbe11ae0",
              "content": "[Context budget exhausted \u2014 synthesize answer from evidence already retrieved]",
              "is_error": false
            }
          ],
          "tokens_used": 0
        },
        {
          "role": "assistant",
          "content": "Based on the available information, there is no direct mention of musculoskeletal or pain-related adverse events specifically associated with LNS-4821. The documented adverse events include fatigue and headache, both of which were reported as grade 1 and either possibly or unlikely related to the treatment [clinical_signal_03_ep_003]. No episodes retrieved from the memory system reference musculoskeletal symptoms or pain-related events in the context of LNS-4821 administration. Therefore, within the current data, such adverse events are not reported.",
          "tokens_used": 3784
        }
      ],
      "tool_calls_made": 3,
      "total_tokens": 10412,
      "wall_time_ms": 9651.109991013072,
      "budget_violations": [
        "Cumulative result token limit exceeded: 3432 > 2048"
      ],
      "refs_cited": [
        "clinical_signal_03_ep_003"
      ]
    },
    "retrieved_ref_ids": [
      "clinical_signal_03_ep_003"
    ],
    "valid_ref_ids": [
      "clinical_signal_03_ep_003"
    ]
  },
  {
    "question": {
      "question_id": "cs03_q20_distractor",
      "scope_id": "clinical_signal_03",
      "checkpoint_after": 25,
      "question_type": "distractor_resistance",
      "prompt": "Is there any relationship between seroconversion rates and the adverse event pattern?",
      "ground_truth": {
        "canonical_answer": "No. Immunogenicity measures including seroconversion rates are not related to the hepatotoxicity signal. The adverse events are driven by a CYP3A4-mediated drug-drug interaction with statins.",
        "required_evidence_refs": [
          "clinical_signal_03_ep_005",
          "clinical_signal_03_ep_023"
        ],
        "key_facts": [
          "the ALT elevation pattern correlates with statin co-administration timing, not with immune activation or antibody response patterns",
          "the hepatic enzyme pattern is consistent with a drug-drug interaction mediated through shared hepatic metabolism pathways, not direct hepatotoxicity"
        ]
      }
    },
    "answer": {
      "question_id": "cs03_q20_distractor",
      "answer_text": "The retrieved documents do not contain explicit information about the relationship between seroconversion rates and adverse event patterns. The search results primarily focus on enrollment data, site-specific statistics, and concomitant medication use (e.g., statins), but none mention seroconversion rates or their correlation with adverse events [clinical_signal_03_ep_020, clinical_signal_03_ep_024, clinical_signal_03_ep_011, clinical_signal_03_ep_007, clinical_signal_03_ep_005, clinical_signal_03_ep_001, clinical_signal_03_ep_012]. \n\nTherefore, based on the available information, no direct relationship between seroconversion rates and adverse event patterns can be established.",
      "turns": [
        {
          "role": "assistant",
          "content": "",
          "tool_calls": [
            {
              "id": "call_7f58b7ef2fb8412491e9ad36",
              "name": "memory_capabilities",
              "arguments": {}
            }
          ],
          "tokens_used": 748
        },
        {
          "role": "tool",
          "tool_results": [
            {
              "tool_call_id": "call_7f58b7ef2fb8412491e9ad36",
              "content": "{\"search_modes\": [\"keyword\", \"semantic\"], \"filter_fields\": [{\"name\": \"scope_id\", \"field_type\": \"string\", \"description\": \"Filter by scope ID\", \"enum_values\": null}, {\"name\": \"start_date\", \"field_type\": \"string\", \"description\": \"Filter episodes after this ISO date\", \"enum_values\": null}, {\"name\": \"end_date\", \"field_type\": \"string\", \"description\": \"Filter episodes before this ISO date\", \"enum_values\": null}], \"max_results_per_search\": 7, \"supports_date_range\": true, \"extra_tools\": [{\"name\": \"batch_retrieve\", \"description\": \"Retrieve multiple full documents by their reference IDs in a single call. PREFER this over calling memory_retrieve multiple times \\u2014 it is far more efficient and uses only one tool call instead of one per document. After memory_search, pass all ref_ids you want to read to this tool.\", \"parameters\": {\"type\": \"object\", \"properties\": {\"ref_ids\": {\"type\": \"array\", \"items\": {\"type\": \"string\"}, \"description\": \"List of reference IDs to retrieve (from search results).\"}}, \"required\": [\"ref_ids\"]}}]}",
              "is_error": false
            }
          ],
          "tokens_used": 0
        },
        {
          "role": "assistant",
          "content": "",
          "tool_calls": [
            {
              "id": "call_30bcdba2be404983a17becb2",
              "name": "memory_search",
              "arguments": {
                "query": "relationship between seroconversion rates and adverse event patterns",
                "limit": 7
              }
            }
          ],
          "tokens_used": 1051
        },
        {
          "role": "tool",
          "tool_results": [
            {
              "tool_call_id": "call_30bcdba2be404983a17becb2",
              "content": "[{\"ref_id\": \"clinical_signal_03_ep_020\", \"text\": \"## 2024-07-15 Daily Operations Summary\\n\\n### Enrollment\\n- Total Randomized: 216\\n- Active: 206\\n- Screen Failures Cumulative: 45\\n- Withdrawals Cumulative: 10\\n\\n#### Sites\\n- Site 01 Enrolled: 22\\n- Site 01 Active: 22\\n- Site 01 Statin Concomitant: 7\\n- Site 02 Enrolled: 16\\n- Site 02 Active: 16\\n- Site 02 Statin Concomitant: 5\\n- Site 03 Enrolled: 20\\n- Site 03 Active: 20\\n- Site 03 Statin Concomitant: 6\\n- Site 04 Enrolled: 14\\n- Site 04 Active: 14\\n- Site 04 Statin Concomitant: 4\\n- Site 05 Enrolled: 18\\n- Site\", \"score\": 0.03177805800756621, \"metadata\": {\"episode_type\": \"signal\", \"phase\": \"escalation\", \"signal_density\": \"high\"}}, {\"ref_id\": \"clinical_signal_03_ep_024\", \"text\": \"## 2024-08-12 Daily Operations Summary\\n\\n### Enrollment\\n- Total Randomized: 244\\n- Active: 236\\n- Screen Failures Cumulative: 49\\n- Withdrawals Cumulative: 8\\n\\n### Sites\\n- Site 01\\n  - Enrolled: 25\\n  - Active: 25\\n  - Statin Concomitant: 6\\n- Site 02\\n  - Enrolled: 18\\n  - Active: 18\\n  - Statin Concomitant: 5\\n- Site 03\\n  - Enrolled: 22\\n  - Active: 22\\n  - Statin Concomitant: 7\\n- Site 04\\n  - Enrolled: 16\\n  - Active: 16\\n  - Statin Concomitant: 5\\n- Site 05\\n  - Enrolled: 20\\n  - Active: 20\\n  - Statin Concomitan\", \"score\": 0.03149801587301587, \"metadata\": {\"episode_type\": \"signal\", \"phase\": \"root_cause\", \"signal_density\": \"high\"}}, {\"ref_id\": \"clinical_signal_03_ep_011\", \"text\": \"## 2024-05-13 Daily Operations Summary\\n\\n### Enrollment\\n- Total Randomized: 189\\n- Active: 182\\n- Screen Failures Cumulative: 27\\n- Withdrawals Cumulative: 7\\n\\n#### Sites\\n- Site 01\\n  - Enrolled: 19\\n  - Active: 19\\n  - Statin Concomitant: 5\\n- Site 02\\n  - Enrolled: 14\\n  - Active: 14\\n  - Statin Concomitant: 3\\n- Site 03\\n  - Enrolled: 17\\n  - Active: 17\\n  - Statin Concomitant: 5\\n- Site 04\\n  - Enrolled: 12\\n  - Active: 12\\n  - Statin Concomitant: 3\\n- Site 05\\n  - Enrolled: 16\\n  - Active: 16\\n  - Statin Concomita\", \"score\": 0.030798389007344232, \"metadata\": {\"episode_type\": \"signal\", \"phase\": \"early_signal\", \"signal_density\": \"low\"}}, {\"ref_id\": \"clinical_signal_03_ep_007\", \"text\": \"## 2024-04-15 Daily Operations Summary\\n\\n### Enrollment\\n- Total Randomized: 160\\n- Active: 156\\n- Screen Failures Cumulative: 15\\n- Withdrawals Cumulative: 4\\n\\n#### Sites\\n- Site 01 Enrolled: 16\\n- Site 01 Active: 16\\n- Site 01 Statin Concomitant: 4\\n- Site 02 Enrolled: 12\\n- Site 02 Active: 12\\n- Site 02 Statin Concomitant: 3\\n- Site 03 Enrolled: 15\\n- Site 03 Active: 15\\n- Site 03 Statin Concomitant: 4\\n- Site 04 Enrolled: 10\\n- Site 04 Active: 10\\n- Site 04 Statin Concomitant: 2\\n- Site 05 Enrolled: 13\\n- Site \", \"score\": 0.029827662395050816, \"metadata\": {\"episode_type\": \"signal\", \"phase\": \"baseline\", \"signal_density\": \"none\"}}, {\"ref_id\": \"clinical_signal_03_ep_005\", \"text\": \"## 2024-04-01 Daily Operations Summary\\n\\n### Enrollment\\n- Total Randomized: 120\\n- Active: 118\\n- Screen Failures Cumulative: 11\\n- Withdrawals Cumulative: 2\\n\\n#### Sites\\n- Site 01 Enrolled: 12\\n- Site 01 Active: 12\\n- Site 01 Statin Concomitant: 4\\n- Site 02 Enrolled: 9\\n- Site 02 Active: 9\\n- Site 02 Statin Concomitant: 3\\n- Site 03 Enrolled: 11\\n- Site 03 Active: 11\\n- Site 03 Statin Concomitant: 3\\n- Site 04 Enrolled: 8\\n- Site 04 Active: 8\\n- Site 04 Statin Concomitant: 2\\n- Site 05 Enrolled: 10\\n- Site 05 A\", \"score\": 0.029513888888888888, \"metadata\": {\"episode_type\": \"signal\", \"phase\": \"baseline\", \"signal_density\": \"none\"}}, {\"ref_id\": \"clinical_signal_03_ep_001\", \"text\": \"## 2024-03-04 Daily Operations Summary\\n\\n### Enrollment\\n- Total Randomized: 40\\n- Active: 40\\n- Screen Failures Cumulative: 2\\n- Withdrawals Cumulative: 0\\n\\n#### Sites\\n- Site 01: \\n  - Enrolled: 4\\n  - Active: 4\\n  - Statin Concomitant: 1\\n- Site 02: \\n  - Enrolled: 3\\n  - Active: 3\\n  - Statin Concomitant: 0\\n- Site 03: \\n  - Enrolled: 3\\n  - Active: 3\\n  - Statin Concomitant: 0\\n- Site 04: \\n  - Enrolled: 2\\n  - Active: 2\\n  - Statin Concomitant: 0\\n- Site 05: \\n  - Enrolled: 3\\n  - Active: 3\\n  - Statin Concomitant:\", \"score\": 0.029437229437229435, \"metadata\": {\"episode_type\": \"signal\", \"phase\": \"baseline\", \"signal_density\": \"none\"}}, {\"ref_id\": \"clinical_signal_03_ep_012\", \"text\": \"## 2024-05-20 Daily Operations Summary\\n\\n### Enrollment\\n- Total Randomized: 192\\n- Active: 186\\n- Screen Failures Cumulative: 21\\n- Withdrawals Cumulative: 6\\n\\n#### Sites\\n- Site 01\\n  - Enrolled: 19\\n  - Active: 19\\n  - Statin Concomitant: 5\\n- Site 02\\n  - Enrolled: 14\\n  - Active: 14\\n  - Statin Concomitant: 3\\n- Site 03\\n  - Enrolled: 18\\n  - Active: 18\\n  - Statin Concomitant: 5\\n- Site 04\\n  - Enrolled: 13\\n  - Active: 13\\n  - Statin Concomitant: 3\\n- Site 05\\n  - Enrolled: 16\\n  - Active: 16\\n  - Statin Concomita\", \"score\": 0.029418126757516764, \"metadata\": {\"episode_type\": \"signal\", \"phase\": \"early_signal\", \"signal_density\": \"low\"}}]",
              "is_error": false
            }
          ],
          "tokens_used": 0
        },
        {
          "role": "assistant",
          "content": "",
          "tool_calls": [
            {
              "id": "call_1031d494164f421f8ac1c01b",
              "name": "memory_search",
              "arguments": {
                "query": "seroconversion rates and adverse events analysis",
                "limit": 7
              }
            }
          ],
          "tokens_used": 3172
        },
        {
          "role": "tool",
          "tool_results": [
            {
              "tool_call_id": "call_1031d494164f421f8ac1c01b",
              "content": "[Context budget exhausted \u2014 synthesize answer from evidence already retrieved]",
              "is_error": false
            }
          ],
          "tokens_used": 0
        },
        {
          "role": "assistant",
          "content": "The retrieved documents do not contain explicit information about the relationship between seroconversion rates and adverse event patterns. The search results primarily focus on enrollment data, site-specific statistics, and concomitant medication use (e.g., statins), but none mention seroconversion rates or their correlation with adverse events [clinical_signal_03_ep_020, clinical_signal_03_ep_024, clinical_signal_03_ep_011, clinical_signal_03_ep_007, clinical_signal_03_ep_005, clinical_signal_03_ep_001, clinical_signal_03_ep_012]. \n\nTherefore, based on the available information, no direct relationship between seroconversion rates and adverse event patterns can be established.",
          "tokens_used": 3361
        }
      ],
      "tool_calls_made": 3,
      "total_tokens": 8332,
      "wall_time_ms": 10441.124458913691,
      "budget_violations": [
        "Cumulative result token limit exceeded: 2697 > 2048"
      ],
      "refs_cited": []
    },
    "retrieved_ref_ids": [],
    "valid_ref_ids": []
  }
]